Registered title, quoted from ClinicalTrials.gov
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07474324, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathological stage III gastric and gastroesophageal junction adenocarcinoma patients (according to the 8th edition of the American Joint Committee on Cancer [AJCC] staging system).
Inclusion criterion 5
Possesses complete imaging and pathological clinical data;
Inclusion criterion 11
Primary stage III gastric or gastroesophageal-junction adenocarcinoma not histologically or cytologically confirmed;
Exclusion criterion 1
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Inclusion criterion 7
Other malignancies within 5 years before screening, except adequately treated cancers considered cured (e.g., thyroid cancer, cervical carcinoma in situ, basal/squamous-cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery);
Exclusion criterion 9
Lactating women;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07474324, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged between 18 and 75 years.
- Have undergone radical resection with D2 or wider lymph node dissection and achieved R0 resection status.
- No prior systemic anti-tumor treatment (i.e., neoadjuvant therapy) before surgery.
- Histopathologically confirmed gastric adenocarcinoma.
- Pathological stage III gastric and gastroesophageal junction adenocarcinoma patients (according to the 8th edition of the American Joint Committee on Cancer [AJCC] staging system).
- HER2 moderate-to-high expression (IHC 3+ or 2+).
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- Expected survival time ≥ 3 months.
- Able to understand the study protocol, voluntarily participate in the study, and provide written informed consent;
- Good compliance and able to cooperate with the treatment regimen specified in this study;
- Possesses complete imaging and pathological clinical data;
- Adequate organ and bone-marrow function.
Exclusion Criteria:
- Primary stage III gastric or gastroesophageal-junction adenocarcinoma not histologically or cytologically confirmed;
- Unable to receive disitamab vedotin or SOX chemotherapy;
- Unable to comply with the required follow-up schedule;
- Unable to accept the treatment regimen specified in this protocol;
- Unable or unwilling to undergo mandated response assessments (e.g., CT imaging);
- Active autoimmune disease;
- History of psychoactive-substance abuse that cannot be discontinued, or any severe/uncontrolled psychiatric disorder, or any severe/uncontrolled systemic disease;
- Any concomitant condition that, in the investigator's opinion, poses significant risk to the subject or could compromise study completion;
- Other malignancies within 5 years before screening, except adequately treated cancers considered cured (e.g., thyroid cancer, cervical carcinoma in situ, basal/squamous-cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery);
- Lactating women;
- Prior neoadjuvant therapy or intra-operative intraperitoneal chemotherapy.
Quoted from ClinicalTrials.gov, NCT07474324, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07474324, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.